×
Click here if you are having issues using your co-pay card or your co-pay is higher than normal at the pharmacy.
close
  • Approved Use: Aimovig® is a prescription medicine used for the preventive treatment of migraine in adults.
Migraine Tracker
Migraine Tracker

Track your migraine with a daily text

This migraine tracking tool is a quick, easy way to track your migraine. It will help you recognize patterns and changes in a monthly email report. All you have to do is:

  • Respond to a daily text
  • Review your monthly report, which will be emailed to you in a calendar format

Tracking your migraine gives you and your doctor important information, which can help you both create a migraine management plan that’s specific to your needs. If you’re ready to start tracking, sign up below!

Have questions? Download the migraine tracker FAQ (PDF).

Before we start, do you have a prescription for Aimovig® (erenumab-aooe)?

Success!
You’re signed up!

So, what’s next? You’ll receive a text message about the migraine tracker that will just need a quick response. Then you’ll be officially enrolled!

The next day, you’ll start receiving a daily text at 8pm to track your migraine. And at the end of the month, a report will be emailed to you based on your daily responses.

Also, if you haven't already, stay in touch and connect with our community on Facebook and Instagram.

text bubble

Thank you
for signing up.

Contact us here

1-833-AIMOVIG (1-833-246-6844)

8AM–9PM ET, Mon–Fri

+ +

Important Safety Information

Who should not use Aimovig®?
Do not use Aimovig if you are allergic to erenumab-aooe or any ingredients in

Who should not use Aimovig? Do not use Aimovig® if you are allergic to erenumab-aooe or any ingredients in Aimovig®. Before starting Aimovig®, tell your healthcare provider (HCP) about all your medical conditions, including if you are pregnant or plan to become pregnant, breastfeeding or plan to breastfeed.

 

Important Safety Information

Who should not use Aimovig®? Do not use Aimovig® if you are allergic to erenumab-aooe or any ingredients in Aimovig®. Before starting Aimovig®, tell your healthcare provider (HCP) about all your medical conditions, including if you are pregnant or plan to become pregnant, breastfeeding or plan to breastfeed. Tell your HCP about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements. What are possible side effects of Aimovig®? Aimovig® may cause serious side effects, including:
  • Allergic reactions. Allergic reactions, including rash or swelling can happen after receiving Aimovig®. This can happen within hours to days after using Aimovig®. Call your HCP or get emergency medical help right away if you have any of the following symptoms of an allergic reaction: swelling of the face, mouth, tongue or throat, or trouble breathing.
  • Constipation with serious complications. Severe constipation can happen after receiving Aimovig®. In some cases people have been hospitalized or needed surgery. Contact your HCP if you have severe constipation or constipation associated with symptoms such as severe or constant belly pain, vomiting, swelling of belly or bloating.
  • High blood pressure. High blood pressure or worsening of high blood pressure can happen after receiving Aimovig®. Contact your healthcare provider if you have an increase in blood pressure.
The most common side effects of Aimovig® are pain, redness, or swelling at the injection site and constipation. These are not all of the possible side effects of Aimovig®. Call your HCP for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Click here for the full Prescribing Information and Patient Product Information.

Approved Use

Aimovig® is a prescription medicine used for the preventive treatment of migraine in adults.
References: 1. Parsabiv® (etelcalcetide) prescribing information, Amgen. 2. Data on file, Amgen; [Summary of Clinical Efficacy; 2015]. 3. Alexander ST, et al. Mol Pharmacol. 2015;88:853-865. 4. Data on file, Amgen; [Report R20130052, 2014]. 5. Chen P, et al. CPT Pharmacometrics Syst Pharmacol. 2016;5:484-494. 6. Sensipar® (cinacalcet) prescribing information, Amgen. 7. Ma JN, et al. J Pharmacol Exp Ther. 2011;337:275-284.